Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Dec;6(24):473.
doi: 10.21037/atm.2018.10.57.

Fatty acid oxidation disorders

J Lawrence Merritt 2nd  1   2 , Marie Norris  2 , Shibani Kanungo  3
Affiliations
Review

Fatty acid oxidation disorders

J Lawrence Merritt 2nd et al. Ann Transl Med. 2018 Dec.

Abstract

Fatty acid oxidation disorders (FAODs) are inborn errors of metabolism due to disruption of either mitochondrial β-oxidation or the fatty acid transport using the carnitine transport pathway. The presentation of a FAOD will depend upon the specific disorder, but common elements may be seen, and ultimately require a similar treatment. Initial presentations of the FAODs in the neonatal period with severe symptoms include cardiomyopathy, while during infancy and childhood liver dysfunction and hypoketotic hypoglycemia are common. Episodic rhabdomyolysis is frequently the initial presentation during or after adolescence; although, these symptoms may develop at any age for most of the FAODs The treatment of all FAOD's include avoidance of fasting, aggressive treatment during illness, and supplementation of carnitine, if necessary. The long-chain FAODs differ by requiring a fat-restricted diet and supplementation of medium chain triglyceride oil and often docosahexaenoic acid (DHA)-an essential fatty acid, crucial for brain, visual, and immune functions and prevention of fat soluble vitamin deficiencies. The FAOD are a group of autosomal recessive disorders associated with significant morbidity and mortality, but early diagnosis on newborn screening (NBS) and early initiation of treatment are improving outcomes. There is a need for clinical studies including randomized, controlled, therapeutic trials to continue to evaluate current understanding and to implement future therapies.

Keywords: Fatty acid oxidation disorders (FAODs); carnitine; hypoketotic hypoglycemia; mitochondrial β-oxidation; trifunctional protein.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Overview of Mitochondrial Fatty Acid Oxidation Metabolism. Dark Green line, mitochondrial outer membrane (Mito OM); light green line, mitochondrial inner membrane (Mito IM); gold line, plasma membrane (PM). FAOD are shown in the red star shapes with associated enzyme defect. AC, Acyl-CoA; ACS, acyl-CoA synthase; CoA, coenzyme A; FA, fatty acids; MC, medium chain; LC, Long Chain; TFP, tri-functional protein complex; C I, complex I of ETC; CT, carnitine transporter defect; CPT1a, Carnitine palmitoyltransferase I; CPT2, carnitine palmitoyltransferase II; CACT, carnitine acylcarnitine translocase; LCHAD, long-chain 3-hydroxy acyl-CoA dehydrogenase; VLCAD, very long chain acyl-CoA dehydrogenase; MCAD, medium-chain acyl-CoA dehydrogenase; SCAD, short-chain acyl-CoA dehydrogenase; MAD, multiple acyl-CoA dehydrogenases; HAD, 3-hydroxyacyl-CoA dehydrogenase.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Rohr F, Calcar SV. Very Long Chain Acyl CoA Dehydrogenase Deficiency (VLCADD). Genetic Metabolic Dietitians International: Nutrition Guidelines. 2008. Available online: http://gmdi.org/Resources/Nutrition-Guidelines/VLCAD. Accessed August 13 2018.
    1. Miller MJ, Burrage LC, Gibson JB, et al. Recurrent ACADVL molecular findings in individuals with a positive newborn screen for very long chain acyl-coA dehydrogenase (VLCAD) deficiency in the United States. Mol Genet Metab 2015;116:139-45. 10.1016/j.ymgme.2015.08.011 - DOI - PMC - PubMed
    1. Collins SA, Sinclair G, McIntosh S, et al. Carnitine palmitoyltransferase 1A (CPT1A) P479L prevalence in live newborns in Yukon, Northwest Territories, and Nunavut. Mol Genet Metab 2010;101:200-4. 10.1016/j.ymgme.2010.07.013 - DOI - PubMed
    1. Clemente FJ, Cardona A, Inchley CE, et al. A Selective Sweep on a Deleterious Mutation in CPT1A in Arctic Populations. Am J Hum Genet 2014;95:584-9. 10.1016/j.ajhg.2014.09.016 - DOI - PMC - PubMed
    1. Prasad C, Johnson JP, Bonnefont JP, et al. Hepatic carnitine palmitoyl transferase 1 (CPT1 A) deficiency in North American Hutterites (Canadian and American): evidence for a founder effect and results of a pilot study on a DNA-based newborn screening program. Mol Genet Metab 2001;73:55-63. 10.1006/mgme.2001.3149 - DOI - PubMed